Related Experiment Video
Updated: Feb 21, 2026

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
Published on: December 28, 2015
Disease reactivation after switching from natalizumab to daclizumab
Timo Uphaus1, Christoph Oberwittler2, Sergiu Groppa1
1Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstr. 1, Mainz, 55131, Germany.
Abstract:
Discontinuation of natalizumab can lead to severe rebound of disease activity in patients with relapsing-remitting multiple sclerosis (RRMS); nevertheless, the treatment regimen in this clinical situation remains controversial. We report the case of a 25-year-old male patient with RRMS who was clinically stable under 3 years of natalizumab before treatment was stopped due to progressive multifocal leucencephalopathy (PML) safety concerns. After initiation of daclizumab, the patient suffered from disease reactivation, which was ultimately controlled by intravenous methylprednisolone and alemtuzumab treatment. Therefore, in some patients, daclizumab might not be sufficient to control disease activity after discontinuing natalizumab treatment.
More Related Videos
Related Concept Videos
Drug toxicity: Idiosyncratic Reactions
Allergic Drug Reactions
Hypersensitivity Reactions: Immune-Complex Reactions
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Hypersensitivity Reactions: Cytolytic Reactions
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

